Microba Life Sciences Ltd. Stock Analysis MAP.AX

Microba Life Sciences Ltd. engages in the provision of microbiome testing, supplements and analysis services as well as developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-04-05. The firm is engaged in the discovery and development of therapeutics for chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. The company offers various platforms, such as Analysis, Discovery, and Therapeutic. Its Analysis platform is an end-to-end solution for microbiome analysis. Using advanced metagenomic sequencing technology and proprietary bioinformatic tools, it provides precise and comprehensive measurement of the human gut microbiome. Its Discovery Platform is a global databank for microbiome discovery and develops new health solutions from the gut microbiome. Its Therapeutic platform is a repeatable platform for microbial therapeutic leads. Its Diagnostic testing products are MetaXplore and MetaPanel. MetaXplore offers a comprehensive gastrointestinal testing solution. MetaPanel is an advanced gastrointestinal pathogen detection panel.